Stock Research: Ipca Laboratories

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Ipca Laboratories

BSE:524494 INE571A01038
76
  • Value
    50
  • Growth
    69
  • Safety
    Safety
    43
  • Combined
    65
  • Sentiment
    78
  • 360° View
    360° View
    76
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Ipca Laboratories Limited is an India-based integrated pharmaceutical company. It manufactures and markets over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs), including brands like Zerodol and Lariago. Its products are sold in over 100 countries across the globe, with 18 manufacturing units in India. In the last fiscal year, the company had a market cap of $4314 million, profits of $657 million, revenue of $1046 million, and 18043 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 76 (better than 76% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Ipca Laboratories are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Ipca Laboratories. The consolidated Growth Rank has a good rank of 69, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 69% of competitors in the same industry. The consolidated Safety Rank at 50 means that the company has a financing structure that is safer than 50% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 78, which means that professional investors are more optimistic about the stock than for 78% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 43, meaning that the share price of Ipca Laboratories is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 57% of alternative stocks in the same industry. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
43 43 53 55
Growth
69 95 65 25
Safety
Safety
50 40 48 91
Sentiment
78 95 14 4
360° View
360° View
76 90 41 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
69 77 19 71
Opinions Change
15 71 50 13
Pro Holdings
n/a 81 43 16
Market Pulse
83 90 9 37
Sentiment
78 95 14 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
43 43 53 55
Growth
69 95 65 25
Safety Safety
50 40 48 91
Combined
65 76 73 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
56 38 45 68
Price vs. Earnings (P/E)
61 52 65 53
Price vs. Book (P/B)
48 43 55 56
Dividend Yield
24 25 27 24
Value
43 43 53 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
65 78 90 57
Profit Growth
63 86 80 8
Capital Growth
45 62 4 58
Stock Returns
63 79 57 31
Growth
69 95 65 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
46 44 42 76
Refinancing
63 52 70 66
Liquidity
44 28 37 84
Safety Safety
50 40 48 91

Similar Stocks

Discover high‑ranked alternatives to Ipca Laboratories and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

NMDC

BSE:526371
Country: India
Industry: Steel
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.